Sign In
Buy CLVT
Clarivate Earnings Calls
| Release date | Apr 29, 2026 |
| EPS estimate | $0.140 |
| EPS actual | $0.180 |
| EPS Surprise | 28.57% |
| Revenue estimate | 569.496M |
| Revenue actual | 585.5M |
| Revenue Surprise | 2.81% |
| Release date | Feb 24, 2026 |
| EPS estimate | $0.160 |
| EPS actual | $0.200 |
| EPS Surprise | 25.00% |
| Revenue estimate | 604.793M |
| Revenue actual | 617M |
| Revenue Surprise | 2.02% |
| Release date | Oct 29, 2025 |
| EPS estimate | $0.160 |
| EPS actual | $0.180 |
| EPS Surprise | 12.50% |
| Revenue estimate | 604.793M |
| Revenue actual | 623.1M |
| Revenue Surprise | 3.03% |
| Release date | Jul 30, 2025 |
| EPS estimate | $0.180 |
| EPS actual | $0.180 |
| Revenue estimate | 570.354M |
| Revenue actual | 621.4M |
| Revenue Surprise | 8.95% |
Last 4 Quarters for Clarivate
Below you can see how CLVT performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Jul 30, 2025 |
| Price on release | $4.05 |
| EPS estimate | $0.180 |
| EPS actual | $0.180 |
| Date | Price |
|---|---|
| Jul 24, 2025 | $4.44 |
| Jul 25, 2025 | $4.53 |
| Jul 28, 2025 | $4.26 |
| Jul 29, 2025 | $4.23 |
| Jul 30, 2025 | $4.05 |
| Jul 31, 2025 | $3.85 |
| Aug 01, 2025 | $3.62 |
| Aug 04, 2025 | $3.68 |
| Aug 05, 2025 | $3.69 |
| 4 days before | -8.78% |
| 4 days after | -8.89% |
| On release day | -4.94% |
| Change in period | -16.89% |
| Release date | Oct 29, 2025 |
| Price on release | $3.49 |
| EPS estimate | $0.160 |
| EPS actual | $0.180 |
| EPS surprise | 12.50% |
| Date | Price |
|---|---|
| Oct 23, 2025 | $3.70 |
| Oct 24, 2025 | $3.65 |
| Oct 27, 2025 | $3.70 |
| Oct 28, 2025 | $3.64 |
| Oct 29, 2025 | $3.49 |
| Oct 30, 2025 | $3.24 |
| Oct 31, 2025 | $3.40 |
| Nov 03, 2025 | $3.54 |
| Nov 04, 2025 | $3.48 |
| 4 days before | -5.68% |
| 4 days after | -0.287% |
| On release day | -7.16% |
| Change in period | -5.95% |
| Release date | Feb 24, 2026 |
| Price on release | $2.35 |
| EPS estimate | $0.160 |
| EPS actual | $0.200 |
| EPS surprise | 25.00% |
| Date | Price |
|---|---|
| Feb 18, 2026 | $1.78 |
| Feb 19, 2026 | $1.78 |
| Feb 20, 2026 | $1.77 |
| Feb 23, 2026 | $1.68 |
| Feb 24, 2026 | $2.35 |
| Feb 25, 2026 | $2.30 |
| Feb 26, 2026 | $2.40 |
| Feb 27, 2026 | $2.30 |
| Mar 02, 2026 | $2.31 |
| 4 days before | 32.02% |
| 4 days after | -1.70% |
| On release day | -2.13% |
| Change in period | 29.78% |
| Release date | Apr 29, 2026 |
| Price on release | $2.86 |
| EPS estimate | $0.140 |
| EPS actual | $0.180 |
| EPS surprise | 28.57% |
| Date | Price |
|---|---|
| Apr 23, 2026 | $2.50 |
| Apr 24, 2026 | $2.45 |
| Apr 27, 2026 | $2.46 |
| Apr 28, 2026 | $2.51 |
| Apr 29, 2026 | $2.86 |
| Apr 30, 2026 | $2.87 |
| May 01, 2026 | $2.79 |
| May 04, 2026 | $2.81 |
| May 05, 2026 | $2.77 |
| 4 days before | 14.40% |
| 4 days after | -3.15% |
| On release day | 0.350% |
| Change in period | 10.80% |
Clarivate Earnings Call Transcript Summary of Q1 2026
Clarivate reported Q1 2026 revenue of $586 million, with organic ACV growth of 1.6% and subscription organic revenue growth of 1.7%. Adjusted EBITDA was $241 million (41% margin, ~200 bps YoY expansion) and free cash flow was ~$79 million. Management used cash to retire $143 million of debt and repurchase stock and bonds. The company reiterated full-year guidance: organic ACV growth of 2%–3%, revenue (including planned disposals) midpoint of ~$2.36 billion, adjusted EBITDA margin near 43% at midpoint, adjusted diluted EPS of ~$0.75, and free cash flow of ~$400 million (about +10% YoY). Key strategic themes: the “value creation plan” (business model optimization toward subscription, improved sales execution, AI-enabled product and internal efficiencies, and portfolio rationalization), active pursuit of a sale of the Life Science & Healthcare business, continued AI product rollouts and partnerships (e.g., Anthropic integration), an 89% subscription mix, improving IP renewals (renewal rates +100 bps in Q1) and an explicit deleveraging plan to reduce net leverage from ~4x toward ~2.5x over several years. Management expects continued margin expansion driven by subscription mix, cost discipline and disposals, and plans to direct free cash flow toward early bond retirements.
